Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Retained Earnings (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Retained Earnings data on record, last reported at -$3.9 million in Q4 2025.

  • For Q4 2025, Retained Earnings rose 99.03% year-over-year to -$3.9 million; the TTM value through Dec 2025 reached -$3.9 million, up 99.03%, while the annual FY2025 figure was -$3.9 million, 99.03% up from the prior year.
  • Retained Earnings reached -$3.9 million in Q4 2025 per LCTX's latest filing, up from -$467.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$2.1 million in Q1 2021 and bottomed at -$467.8 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$186.4 million, with a median of -$4.1 million recorded in 2025.
  • Peak YoY movement for Retained Earnings: plummeted 16360.26% in 2022, then soared 99.32% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$3.4 million in 2021, then decreased by 4.02% to -$3.6 million in 2022, then plummeted by 10677.26% to -$384.9 million in 2023, then decreased by 4.84% to -$403.5 million in 2024, then soared by 99.03% to -$3.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$3.9 million in Q4 2025, -$467.8 million in Q3 2025, and -$4.1 million in Q2 2025.